<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacologic therapy in survivors of sudden cardiac arrest</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacologic therapy in survivors of sudden cardiac arrest</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacologic therapy in survivors of sudden cardiac arrest</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip J Podrid, MD, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Manaker, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Samuel Lévy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden cessation of cardiac activity with hemodynamic collapse, typically due to sustained ventricular tachycardia (VT) or ventricular fibrillation (VF). The event is referred to as SCA (or aborted SCD) if an intervention (eg, defibrillation, cardioversion, or drug therapy) or spontaneous reversion restores circulation, while the SCD terminology is employed if the patient dies. However, the use of SCD to describe both fatal and nonfatal cardiac arrest often persists by convention. (See  <a class="medical medical_review" href="/z/d/html/963.html" rel="external">"Overview of sudden cardiac arrest and sudden cardiac death", section on 'Definitions'</a>.)</p><p>The treatment of SCA consists of acute resuscitation using standardized advanced cardiac life-support protocols, followed by therapy to prevent recurrent arrhythmias and SCD. Patients who survive SCA caused by VT/VF not due to a reversible cause generally receive an implantable cardioverter-defibrillator (ICD). Antiarrhythmic drugs are used in select patients as adjunctive therapy, or as primary therapy when an ICD is not indicated or refused by the patient. This approach, endorsed by numerous professional societies, is based on the significant survival benefit of patients receiving an ICD compared with antiarrhythmic drugs alone or no therapy.</p><p>This topic will review the role of pharmacologic therapy in survivors of SCA, with an emphasis on the role of antiarrhythmic drugs. Issues related to the acute management of SCA, the evaluation of survivors, and the utility of an ICD, arrhythmic surgery, or radiofrequency ablation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/970.html" rel="external">"Cardiac evaluation of the survivor of sudden cardiac arrest"</a> and  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H780748951"><span class="h1">INDICATIONS FOR PHARMACOLOGIC THERAPY</span><span class="headingEndMark"> — </span>Nearly all survivors of SCA without a reversible cause should be evaluated for placement of an ICD. Because an ICD treats, but does not prevent, arrhythmias, patients who have arrhythmias with symptoms or device discharges may require adjunctive antiarrhythmic therapy.</p><p>In addition to ICD therapy for survivors of SCA, there are three main indications for concomitant antiarrhythmic drug therapy [<a href="#rid1">1-3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>To reduce the frequency of ventricular arrhythmias in patients with frequent ICD shocks. In one analysis, the occurrence of frequent ICD shocks was the primary reason for adding an antiarrhythmic drug (64 percent) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To suppress supraventricular arrhythmias that may cause symptoms or interfere with ICD function, potentially resulting in "inappropriate" shocks. "Inappropriate" shocks result from non-life-threatening arrhythmias which meet the programmed parameters for ICD therapy, primarily based upon rate (eg, atrial fibrillation with a rapid ventricular response exceeding the programmed threshold for delivering a shock). "Inappropriate" shocks have been reported in up to 29 percent of ICD patients and can have a substantial impact on the patient’s quality of life [<a href="#rid4">4</a>]. These shocks are caused by a variety of arrhythmias including sinus tachycardia, atrial tachycardia, atrial flutter,<strong> </strong>atrial fibrillation, and nonsustained VT (NSVT) [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/989.html" rel="external">"Cardiac implantable electronic devices: Long-term complications", section on 'Inappropriate shocks'</a>.)</p><p></p><p class="bulletIndent1">More sophisticated programming features of current-generation ICDs may allow the device to ignore clinically unimportant and non-life-threatening arrhythmias rather than delivering an unnecessary shock. (See  <a class="medical medical_review" href="/z/d/html/113776.html" rel="external">"Implantable cardioverter-defibrillators: Optimal programming"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To reduce the ventricular rate of VT so that it is better tolerated hemodynamically and/or more amenable to termination by antitachycardia pacing or low-energy cardioversion, a therapy that may be delivered by the ICD.</p><p></p><p class="headingAnchor" id="H109254618"><span class="h1">CHOICE OF PHARMACOLOGIC THERAPY</span><span class="headingEndMark"> — </span>For patients with an ICD who require adjunctive antiarrhythmic therapy due to ongoing ventricular arrhythmias, we recommend treatment with the combination of <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> plus a beta blocker (given that amiodarone also has beta-blocking effects) rather than treatment with amiodarone alone or other antiarrhythmic agents. On occasion, therapy with <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">mexiletine</a> or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> may be useful. In general, the class I antiarrhythmic drugs are not used, as the majority of patients with SCA have structural heart disease, and as per the U S Food and Drug Administration, these drugs are not recommended in patients with structural heart disease. </p><p>Pharmacologic therapy, in the form of beta blockers and antiarrhythmic medications, can be helpful in controlling ventricular arrhythmias in survivors of SCA. Virtually all patients who have survived SCA should be considered for beta blocker therapy. However, due to the efficacy of the ICD in treating sustained ventricular tachyarrhythmias and improving mortality, antiarrhythmic drugs (ie, class I and III antiarrhythmic drugs) are generally reserved for use in select patients as adjunctive therapy, or as primary therapy when an ICD is not indicated or refused by the patient. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Empiric versus guided pharmacologic therapy</span><span class="headingEndMark"> — </span>Empiric pharmacologic therapy for SCA survivors, primarily with beta blockers and/or an antiarrhythmic drug, is an effective approach for survivors of SCA who have refused ICD placement or are not candidates for an ICD. Beta blockers (which work only by blocking the effect of sympathetic activity on the beta receptors in the myocardium but have no direct effects on myocardial function) have some efficacy with relatively few side effects, while for most patients, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> is the most efficacious antiarrhythmic drug for preventing recurrent ventricular arrhythmias.</p><p>In the past, the choice of antiarrhythmic drug was guided by objective criteria based upon either noninvasive (ambulatory electrocardiogram [ECG] monitoring) or invasive testing (electrophysiologic studies). An effective drug, identified by either technique, was noted to prevent recurrent arrhythmia and potentially improve survival compared with no therapy or an ineffective drug [<a href="#rid6">6-13</a>]. In current practice, however, when pharmacologic therapy is administered to a patient with or without (because of refusal or noncandidacy for) an ICD, empiric treatment with beta blockers and/or <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> is the preferred approach. Other antiarrhythmic drugs (for example <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">mexiletine</a> or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>) are considered if there is recurrent arrhythmia despite therapy with amiodarone and/or a beta blocker.</p><p class="headingAnchor" id="H780749578"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>Nearly all patients who have survived SCA should receive a beta blocker as part of their therapy. Beta blockers are not generally considered to be adequate monotherapy and should be used in conjunction with an antiarrhythmic drug for most patients resuscitated from SCA due to VT or ventricular fibrillation (VF). However, the associated anti-adrenergic effects of beta blockers may be effective at reducing both arrhythmias and SCA when no specific antiarrhythmic treatment is given. In an analysis from the AVID trial, patients who were discharged from the hospital on a beta blocker had a mortality reduction compared with those patients not receiving a beta blocker [<a href="#rid14">14</a>].</p><p>Most SCA survivors will have multiple indications for a beta blocker (eg, post-myocardial infarction, heart failure, etc) from which they derive clinical benefit. Beta blockers reduce the incidence of sudden death and total mortality in patients in whom sympathetic stimulation may play a role; for example, those with a recent myocardial infarction and in those with symptomatic heart failure or congenital long QT syndrome. However, even in the absence of any additional indications, beta blockers should be used as part of the medical regimen following SCA due to VT/VF. (See  <a class="medical medical_review" href="/z/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a> and  <a class="medical medical_review" href="/z/d/html/988.html" rel="external">"Congenital long QT syndrome: Treatment"</a>.)</p><p>Beta blockers can potentiate the effects of class I antiarrhythmic drugs by preventing the effect of sympathetic stimulation on reversing the depressant effect on slowing conduction. They can also potentiate the action of class III antiarrhythmic drugs by preventing the sympathetic effect on shortening repolarization.</p><p class="headingAnchor" id="H5"><span class="h2">Antiarrhythmic drugs</span><span class="headingEndMark"> — </span>Among antiarrhythmic medications, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> is the most effective for preventing recurrent ventricular tachyarrhythmias, although <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">mexiletine</a> or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> are also efficacious for reducing recurrent ventricular arrhythmias. We prefer empiric therapy with amiodarone for treatment immediately following SCA in patients with recurrent ventricular tachyarrhythmias as well as for those who have refused (or are not candidates for) ICD placement [<a href="#rid15">15</a>]. Following stabilization of the patient, if there are concerns about potential toxicity related to amiodarone, particularly for anticipated long-term use, mexiletine or sotalol may be considered. On occasion, mexiletine may be added to therapy with amiodarone if there is recurrent arrhythmia despite therapy with this drug.<strong> </strong>(See  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a>.)</p><p class="headingAnchor" id="H29708509"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Several clinical trials and systematic reviews have evaluated the efficacy of antiarrhythmic drugs as adjuvant therapy in ICD patients [<a href="#rid5">5,16-21</a>]. There were significant differences in trial methodologies, which limit direct comparisons. <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> has generally been the most effective antiarrhythmic drug for preventing ventricular arrhythmias (and associated ICD shocks).</p><p class="bulletIndent1"><span class="glyph">●</span>In one systematic review which included eight randomized trials involving 1889 patients, there was significant heterogeneity among the trials, including variation on the active therapy, control therapy, and outcomes assessed, and the results were divided into those trials that compared class III antiarrhythmic drugs (usually <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>) with beta blockers, and those trials that compared class III drugs (sotalol, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, and azimilide) with placebo or no antiarrhythmic therapy [<a href="#rid20">20</a>]. Key findings included:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> in combination with a beta blocker significantly reduced the incidence of shocks compared with beta blocker alone (hazard ratio [HR] 0.27, 95% CI 0.14-0.52). These results were largely driven by the OPTIC trial.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">Sotalol</a> (which has class III action as well as beta-blocking activity) reduced the incidence of ICD shocks when compared with placebo (HR 0.55, 95% CI 0.4-0.78). There was also a trend toward fewer shocks in patients treated with sotalol versus another beta blocker.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment with either azimilide or <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> resulted in nonsignificant trends towards reduction in total ICD shocks (generally due to a decrease in supraventricular arrhythmias) compared with placebo. However, the incidence of appropriate ICD therapies (shocks plus antitachycardia pacing) was significantly reduced by azimilide (HR 0.31, 95% CI 0.29-0.34). However, azimilide is not an available antiarrhythmic drug. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second systematic review of 17 randomized trials involving 5875 patients, patients taking an antiarrhythmic drug had significantly fewer ICD shocks compared with those not on an antiarrhythmic (odds ratio [OR] 0.59, 95% CI 0.36-0.96) [<a href="#rid22">22</a>]. However, the reduction in shocks seen in patients receiving an antiarrhythmic drug was not associated with improved survival (OR 1.07, 95% CI 0.72-1.59).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the OPTIC trial, a multicenter trial that randomized 412 patients with an ICD to treatment with a beta blocker alone, a beta blocker plus <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> alone, the rate of any ICD shock at one year was significantly lower with amiodarone plus a beta blocker than with sotalol or a beta blocker alone (10.3 versus 24.3 and 38.5 percent, respectively) [<a href="#rid16">16</a>]. There was a trend toward fewer total ICD shocks in the sotalol group compared with beta blockers alone; however, sotalol had no significant effect compared with a beta blocker alone in reducing the incidence of appropriate shocks or antitachycardia pacing.</p><p></p><p>Another major advantage of <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> is a very low frequency of proarrhythmia. Although amiodarone can markedly prolong the QT/QTc interval, torsades de pointes is rare. However, caution is necessary when amiodarone is given with other drugs that can prolong the QT interval or therapy is complicated by hypokalemia or hypomagnesemia. Caution is necessary when combining amiodarone with a beta blocker, as amiodarone also has beta blocking effects and significant bradycardia or AV block may occur. This is not a concern in patients who have an ICD, as there is backup pacing. However, for patients without an ICD or pacemaker this should be considered and patients should be monitored carefully. (See  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a> and  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p class="headingAnchor" id="H29708855"><span class="h3">Administration</span><span class="headingEndMark"> — </span>When patients are started on an antiarrhythmic drug, they should have a baseline ECG prior to drug initiation and then serial ECGs for the first two to three days, particularly to monitor heart rate and assess for any significant QT/QTc interval prolongation.</p><p class="headingAnchor" id="H29708862"><span class="h4">Amiodarone</span><span class="headingEndMark"> — </span>The initial dosing of <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> will vary depending on the route (intravenous [IV] or oral) as well as the clinical situation  (<a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with electrical storm or incessant VT, we recommend IV <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> (150 mg IV push, followed by 1 mg/minute IV infusion for six hours, followed by 0.5 mg/minute IV infusion for 18 additional hours) as the initial antiarrhythmic agent. (See  <a class="medical medical_review" href="/z/d/html/1058.html" rel="external">"Electrical storm and incessant ventricular tachycardia", section on 'Initial antiarrhythmic medical therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have been on IV therapy for more than two weeks, we start maintenance oral <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> at a dose of 200 to 400 mg/day. (See  <a class="medical medical_review" href="/z/d/html/926.html" rel="external">"Amiodarone: Clinical uses", section on 'Amiodarone for ventricular arrhythmias'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have been on IV therapy for one to two weeks, we start an intermediate maintenance oral <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> dose of 400 to 800 mg/day until an adequate loading dose has been achieved, then the dose should be reduced to the usual maintenance dose of 200 mg/day. The recommended IV loading dose is 10 to 15 grams or the oral equivalent. As oral amiodarone is approximately 50 percent bioavailable, a total of 20 to 30 grams of oral amiodarone is equivalent to the IV loading dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have been on IV therapy for one week or less, we usually start with a full oral <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> loading dose of 400 to 1200 mg/day (typically in two or three divided doses). This should be continued until a total loading dose of at least<strong> </strong>10<sub> </sub>grams has been received, then the dose should be reduced to the usual maintenance dose of 200 mg/day.</p><p></p><p class="headingAnchor" id="H29708905"><span class="h4">Sotalol</span><span class="headingEndMark"> — </span>In contrast to <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> is not universally available in IV form. Bradycardic and proarrhythmic events (especially due to QT/QTc prolongation) can occur after the initiation of sotalol therapy and with each upward dosing adjustment. As a result, sotalol should be initiated and doses increased in a hospital with facilities for cardiac rhythm monitoring and assessment.</p><p class="bulletIndent1"><span class="glyph">●</span>We start <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> at a dose of 80 mg twice daily, with dose adjustments at three-day intervals once steady-state plasma concentrations have been achieved and the QT interval has been reviewed on a surface ECG. Patients with renal insufficiency require a modification of the dosing interval. (See  <a class="medical medical_review" href="/z/d/html/925.html" rel="external">"Clinical uses of sotalol", section on 'Dosing'</a>.)</p><p></p><p class="headingAnchor" id="H1506250640"><span class="h4">Mexiletine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">Mexiletine</a>, which is a lidocaine-like antiarrhythmic drug, is only available for oral use. It is often used with or without <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> for treating patients with an ICD who have ventricular arrhythmias that are of concern. The usual dose is 200 to 400 mg three times daily. </p><p class="headingAnchor" id="H7"><span class="h2">Treatment of breakthrough arrhythmias</span><span class="headingEndMark"> — </span>Patients who have recurrent, or breakthrough, arrhythmias resulting in repeat ICD shocks or sudden cardiac arrest in spite of therapy with a beta blocker and/or antiarrhythmic drug represent a significant clinical challenge. As with the occurrence of any ventricular arrhythmia, any identifiable reversible causes (eg, myocardial ischemia, electrolyte disturbances) should be corrected. In the absence of any reversible causes, we approach treatment in the following way:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are taking only a beta blocker, we add an antiarrhythmic drug, ideally <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are taking only an antiarrhythmic drug, we add a beta blocker.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are taking both a beta blocker and an antiarrhythmic drug, treatment options include upward titration of either or both existing drugs or the discontinuation of the current antiarrhythmic drug in favor of an alternative antiarrhythmic drug. We prefer to first increase the dose of the beta blocker and the current antiarrhythmic drug to the maximum recommended dose (or maximum tolerated dose if side effects arise). If this approach is ineffective and the patient continues to have recurrent ventricular arrhythmias and shocks, we would consider stopping the current antiarrhythmic drug and initiating treatment with another agent.</p><p></p><p class="bulletIndent1">Another important option for patients with recurrent arrhythmia despite <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> and beta blocker is the addition of a class I antiarrhythmic agent  (<a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">table 2</a>) that does not alter the QT/QTc interval (ie, <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">mexiletine</a> or <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with recurrent ventricular tachyarrhythmia despite the use of multiple antiarrhythmic drugs, cardiac ablation is often the next step in management. Further details on the treatment of refractory VT can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1040.html" rel="external">"Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis", section on 'Radiofrequency catheter ablation'</a>.) </p><p></p><p class="headingAnchor" id="H12"><span class="h1">IMPACT ON ICD THERAPIES</span><span class="headingEndMark"> — </span>The primary goal of using blockers and/or antiarrhythmic drugs in patients with an ICD is to minimize the frequency of recurrent ventricular arrhythmias, thereby decreasing the likelihood of the patient receiving additional ICD shocks. Beyond reducing the likelihood of ICD shocks, however, antiarrhythmic drug therapy may impact the efficacy of ICD therapies by potentially increasing defibrillation thresholds beyond the device’s capability to defibrillate or by slowing the ventricular rates of any recurrent sustained tachyarrhythmias below the device’s threshold for arrhythmia detection.</p><p class="headingAnchor" id="H20200220"><span class="h2">Alterations in DFTs</span><span class="headingEndMark"> — </span>Any antiarrhythmic drug can potentially alter the defibrillation threshold (DFT), although the effect has been most pronounced with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> and its major metabolite desethylamiodarone, which increase the DFT in a dose-dependent fashion [<a href="#rid23">23-25</a>]. DFT testing has historically been performed at the time of ICD implantation, although the routine necessity for this evaluation with the current generation of ICDs has been questioned. However, repeat DFT testing may be warranted after the initiation of amiodarone if there is concern about rising DFT thresholds (as may occur in certain clinical situations, including atrial fibrillation, hypertension, and left ventricular hypertrophy).</p><p>In the report on the efficacy of routine ICD testing discussed above, 71 patients had an ICD test due to the initiation or dose-adjustment of an antiarrhythmic drug (primarily <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>), and the ICD failed to defibrillate only two patients [<a href="#rid26">26</a>]. The role of ICD testing after the initiation of antiarrhythmic therapy was more directly assessed in a substudy of the OPTIC trial, in which 94 patients underwent serial ICD testing to determine the impact of each of three drug regimens (beta blockers, amiodarone plus a beta blocker, and sotalol) on DFTs [<a href="#rid27">27</a>]. At a mean follow-up of 60 days after drug initiation, the mean DFT decreased from baseline in the patients assigned to beta blockers or sotalol (8.8 to 7.1 and 8.1 to 7.2 joules, respectively), while among patients taking amiodarone there was a nonsignificant increase in the mean DFT from 8.5 to 9.8 joules. Given the relatively small number of patients in each arm of this study, the small mean increase in DFT does not preclude the possibility that there may be a larger increase in some patients. Thus, the necessity for ICD testing after the initiation of antiarrhythmic drugs, primarily amiodarone, remains uncertain.</p><p class="headingAnchor" id="H20200233"><span class="h2">Programming changes for VT detection</span><span class="headingEndMark"> — </span>In patients receiving chronic antiarrhythmic drug therapy, the rate of recurrent VT is often slower than the rate seen during the index arrhythmia. Thus, it is common practice to lower the VT detection rate when initiating antiarrhythmic drug therapy; the specific detection threshold rate is determined by the characteristics of the patient’s prior events. However, reducing the VT detection rate can have both positive and negative consequences for the patient:</p><p class="bulletIndent1"><span class="glyph">●</span>If the VT detection rate is reduced and the ICD therapy program includes antitachycardia pacing (ATP), episodes of slow VT may be terminated with ATP before the patient is aware of the event.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the detection rate is set too low, the ICD will not treat the arrhythmia unless it accelerates above the detection rate or progresses to ventricular fibrillation (VF). Thus, some patients who have their detection threshold rate decreased may not receive ICD treatments during episodes of slow VT and may have symptomatic VT (eg, syncope, palpitations, chest pain, dyspnea, or even SCA).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the detection rate is lower, there is an increased potential for detecting sinus tachycardia or supraventricular arrhythmias that may be above the detection rate. This results in inappropriate ICD therapies (ie, shock or overdrive pacing).</p><p></p><p>Close follow-up with remote device interrogation can help determine whether new VT detection settings are appropriate.</p><p class="headingAnchor" id="H2398151693"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">"Society guideline links: Ventricular arrhythmias"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/117075.html" rel="external">"Society guideline links: Basic and advanced cardiac life support in adults"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction </strong>– Because of the survival benefit associated with an implantable cardioverter-defibrillator (ICD) compared with antiarrhythmic therapy alone, most survivors of sudden cardiac arrest (SCA) due to ventricular tachycardia (VT) or ventricular fibrillation (VF) not associated with a reversible cause should receive an ICD. Antiarrhythmic drugs can be considered as the primary therapy when an ICD is not indicated or refused by the patient. (See <a class="local">'Indications for pharmacologic therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for pharmacotherapy </strong>–<strong> </strong>Nearly all patients who have survived SCA should receive a beta blocker as part of their therapy, which may also provide additional antiarrhythmic benefits. (See <a class="local">'Empiric versus guided pharmacologic therapy'</a> above.)</p><p></p><p class="bulletIndent1">Because an ICD does not prevent arrhythmias, patients who have arrhythmias (ventricular or supraventricular) with symptoms or device discharges may require adjunctive antiarrhythmic therapy or consideration of catheter ablation. The three main indications for concomitant antiarrhythmic drug therapy are (see <a class="local">'Indications for pharmacologic therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>To reduce the frequency of ventricular arrhythmias in patients with frequent ICD shocks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>To suppress other arrhythmias that cause symptoms or interfere with ICD function (eg, causing "inappropriate" shocks).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>To reduce the ventricular rate of VT so that it is better tolerated hemodynamically and more amenable to termination by anti-tachycardia pacing or low-energy cardioversion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of pharmacotherapy </strong>– For patients with an ICD who require adjunctive antiarrhythmic therapy due to ongoing arrhythmias, we recommend treatment with the combination of <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> plus a beta blocker rather than treatment with amiodarone alone or other antiarrhythmic agents (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). This approach is especially preferred in patients with significant left ventricular dysfunction who require adjunctive antiarrhythmic therapy, since amiodarone does not exacerbate heart failure and is less proarrhythmic than other agents. (See <a class="local">'Choice of pharmacologic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on ICD therapies </strong>– Antiarrhythmic drug therapy may impact the efficacy of ICD therapies by potentially increasing defibrillation thresholds beyond the device’s capability to defibrillate or by slowing the ventricular rates of any recurrent sustained tachyarrhythmias below the device’s threshold for arrhythmia detection.(See <a class="local">'Impact on ICD therapies'</a> above.)</p><p></p><p class="headingAnchor" id="H2023371457"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thanks Jie Cheng, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Knilans TK, Prystowsky EN. Antiarrhythmic drug therapy in the management of cardiac arrest survivors. Circulation 1992; 85:I118.</a></li><li><a class="nounderline abstract_t">Manz M, Jung W, Lüderitz B. Interactions between drugs and devices: experimental and clinical studies. Am Heart J 1994; 127:978.</a></li><li><a class="nounderline abstract_t">Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 2001; 142:520.</a></li><li><a class="nounderline abstract_t">Nanthakumar K, Paquette M, Newman D, et al. Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators. Am Heart J 2000; 139:797.</a></li><li><a class="nounderline abstract_t">Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999; 340:1855.</a></li><li><a class="nounderline abstract_t">Kim SG. The management of patients with life-threatening ventricular tachyarrhythmias: programmed stimulation or Holter monitoring (either or both)? Circulation 1987; 76:1.</a></li><li><a class="nounderline abstract_t">Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med 1988; 318:19.</a></li><li><a class="nounderline abstract_t">Graboys TB, Lown B, Podrid PJ, DeSilva R. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol 1982; 50:437.</a></li><li><a class="nounderline abstract_t">Lampert S, Lown B, Graboys TB, et al. Determinants of survival in patients with malignant ventricular arrhythmia associated with coronary artery disease. Am J Cardiol 1988; 61:791.</a></li><li><a class="nounderline abstract_t">Vlay SC, Kallman CH, Reid PR. Prognostic assessment of survivors of ventricular tachycardia and ventricular fibrillation with ambulatory monitoring. Am J Cardiol 1984; 54:87.</a></li><li><a class="nounderline abstract_t">Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329:445.</a></li><li><a class="nounderline abstract_t">Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329:452.</a></li><li><a class="nounderline abstract_t">Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 1983; 308:1436.</a></li><li><a class="nounderline abstract_t">Exner DV, Reiffel JA, Epstein AE, et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 1999; 34:325.</a></li><li><a class="nounderline abstract_t">Weinberg BA, Miles WM, Klein LS, et al. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 1993; 125:109.</a></li><li><a class="nounderline abstract_t">Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006; 295:165.</a></li><li><a class="nounderline abstract_t">Dorian P, Borggrefe M, Al-Khalidi HR, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004; 110:3646.</a></li><li><a class="nounderline abstract_t">Singer I, Al-Khalidi H, Niazi I, et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 2004; 43:39.</a></li><li><a class="nounderline abstract_t">Kühlkamp V, Mewis C, Mermi J, et al. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol 1999; 33:46.</a></li><li><a class="nounderline abstract_t">Ferreira-González I, Dos-Subirá L, Guyatt GH. Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. Eur Heart J 2007; 28:469.</a></li><li><a class="nounderline abstract_t">Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. Am J Cardiol 1993; 72:280.</a></li><li><a class="nounderline abstract_t">Ha AH, Ham I, Nair GM, et al. Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm 2012; 9:2068.</a></li><li><a class="nounderline abstract_t">Zhou L, Chen BP, Kluger J, et al. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998; 31:1672.</a></li><li><a class="nounderline abstract_t">Pelosi F Jr, Oral H, Kim MH, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000; 11:736.</a></li><li><a class="nounderline abstract_t">Nielsen TD, Hamdan MH, Kowal RC, et al. Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. Am J Cardiol 2001; 88:446.</a></li><li><a class="nounderline abstract_t">Brunn J, Böcker D, Weber M, et al. Is there a need for routine testing of ICD defibrillation capacity? Results from more than 1000 studies. Eur Heart J 2000; 21:162.</a></li><li><a class="nounderline abstract_t">Hohnloser SH, Dorian P, Roberts R, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006; 114:104.</a></li></ol></div><div id="topicVersionRevision">Topic 972 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728494" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antiarrhythmic drug therapy in the management of cardiac arrest survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8160602" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Interactions between drugs and devices: experimental and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11526368" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10783212" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369848" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3594762" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The management of patients with life-threatening ventricular tachyarrhythmias: programmed stimulation or Holter monitoring (either or both)?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336381" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6180622" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3354443" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Determinants of survival in patients with malignant ventricular arrhythmia associated with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6741843" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prognostic assessment of survivors of ventricular tachycardia and ventricular fibrillation with ambulatory monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8332149" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8332150" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6855814" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Determinants of survival in patients with ventricular tachyarrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440140" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417505" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Five-year follow-up of 589 patients treated with amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403928" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15533855" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715180" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9935007" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227788" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8342505" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23108056" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626850" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10921789" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of chronic amiodarone therapy on defibrillation energy requirements in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11545776" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637090" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Is there a need for routine testing of ICD defibrillation capacity? Results from more than 1000 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16818810" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
